SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Instagram Outage Disrupts Thousands of U.S. Users 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
ROCKVILLE, Md., Sept. 07, 2016 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 in New York.
A live webcast of REGENXBIO’s presentation is scheduled to begin at 12:55 p.m. ET and will feature a fireside chat with Kenneth T. Mills, President and Chief Executive Officer. The live webcast can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation.
REGENXBIO representatives will also attend the Bank of America Merrill Lynch Global Healthcare Conference on Friday, September 16, 2016 in London to meet one-on-one with investors, analysts and other potential corporate partners.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of June 30, 2016, REGENXBIO's NAV Technology Platform was being applied in the development of 29 product candidates for a variety of diseases, including five internally developed candidates and 24 partnered candidates developed by REGENXBIO's licensees.
CONTACT: Investors Elizabeth Broder, 646-378-2945 [email protected] Media Laura Bagby, 312-448-8098 [email protected]
